Regulatory November 7, 2019

Lipidor Announces Last Patient Out in Calcipotriol/AKVANO spray (AKP01) Phase III Study Targeting Psoriasis

Lipidor AB (publ) today reports that the last patient has completed treatment in the phase III study evaluating the efficacy of using a sprayable calcipotriol product against mild to moderate psoriasis. Results from the study are expected to be presented in December 2019.

Lipidor has developed a sprayable calcipotriol product, Calcipotriol/AKVANO 50 µg/g cutaneous solution (AKP01), formulated with the company’s lipid-based technology in order to provide more precise dosing, increased comfort, and non-touch treatment to patients.

The phase III study is a comparative, randomized and placebo-controlled study with data collected from 277 patients treated at 14 clinics across India treated over a period of 8 weeks. The study compares the therapeutic equivalence of the calcipotriol spray with a marketed calcipotriol ointment. 

The study is conducted in collaboration with Cerbios-Pharma SA, specialized in the development and manufacturing of chemical and biological APIs, and Cadila Pharmaceuticals Ltd of India, which is responsible for the study. 

Psoriasis is a chronic disease in which the immune system plays a central part. The disease affects between 2 and 3 percent of the world’s population. 


This information above was provided by Lipidor according to EU Market Abuse Regulations. The information was provided, through the below contact person, for publication on 7 November 2019 at 11.00am (CET).